EARLY_POD_1-ai

May 14, 2026 06:10 · 13:37 · English · Whisper Large V3 · 4 Speaker
Transkrip ini kadaluarsa hari ini. Tingkatkan untuk penyimpanan permanen →
Indeks Kuliah
Tampilkan saja
0:00
S… Speaker 1 (EARLY_POD_1-ai)
All right,
0:00
S… Speaker 1 (EARLY_POD_1-ai)
Dr.
0:01
S… Speaker 1 (EARLY_POD_1-ai)
Ratul, you are the leading minds in the country about all things GLP -1,
0:05
S… Speaker 1 (EARLY_POD_1-ai)
weight loss and related.
0:06
S… Speaker 1 (EARLY_POD_1-ai)
Thank you so much for joining us.
0:08
S… Speaker 2 (EARLY_POD_1-ai)
Thank you.
0:10
S… Speaker 2 (EARLY_POD_1-ai)
Thank you for I will be here.
0:11
S… Speaker 1 (EARLY_POD_1-ai)
Of course.
0:11
S… Speaker 1 (EARLY_POD_1-ai)
Please introduce yourself.
0:13
S… Speaker 2 (EARLY_POD_1-ai)
I am Dr.
0:14
S… Speaker 2 (EARLY_POD_1-ai)
Atun Dhingra.
0:15
S… Speaker 2 (EARLY_POD_1-ai)
I am an endocrinologist currently practicing in Srinagaragar.
0:19
S… Speaker 2 (EARLY_POD_1-ai)
And I'm also heading a department of epidemiology at Dr.
0:22
S… Speaker 1 (EARLY_POD_1-ai)
S. S.
0:22
S… Speaker 2 (EARLY_POD_1-ai)
Tantia Medical College in Stigel.
0:24
S… Speaker 1 (EARLY_POD_1-ai)
Amazing.
0:25
S… Speaker 1 (EARLY_POD_1-ai)
So, let's start from here.
0:26
S… Speaker 1 (EARLY_POD_1-ai)
What are GLP medications and how are weight loss?
0:30
S… Speaker 2 (EARLY_POD_1-ai)
So,
0:31
S… Speaker 2 (EARLY_POD_1-ai)
GLP -1 is a hormone.
0:35
S… Speaker 2 (EARLY_POD_1-ai)
Today, we thought that the weight that we eat
0:39
S… Speaker 2 (EARLY_POD_1-ai)
and that we don't eat,
0:40
S… Speaker 2 (EARLY_POD_1-ai)
is the difference.
0:41
S… Speaker 2 (EARLY_POD_1-ai)
But actually,
0:42
S… Speaker 2 (EARLY_POD_1-ai)
when we had a psychiatric surgery,
0:43
S… Speaker 2 (EARLY_POD_1-ai)
we understood that this is only the change of
0:48
S… Speaker 2 (EARLY_POD_1-ai)
eating. This is our mind of a hormone system problem.
0:51
S… Speaker 2 (EARLY_POD_1-ai)
When we have a psychiatric surgery,
0:53
S… Speaker 2 (EARLY_POD_1-ai)
we have a GLP -1 hormone in it.
0:57
S… Speaker 2 (EARLY_POD_1-ai)
When we have a research on this research,
1:00
S… Speaker 2 (EARLY_POD_1-ai)
we have made it out of our patients.
1:16
S… Speaker 1 (EARLY_POD_1-ai)
All right.
1:16
S… Speaker 1 (EARLY_POD_1-ai)
Wow. Sounds very powerful.
1:18
S… Speaker 1 (EARLY_POD_1-ai)
So, how much weight loss can be for obese people?
1:21
S… Speaker 2 (EARLY_POD_1-ai)
It depends on which molecules you choose.
1:24
S… Speaker 2 (EARLY_POD_1-ai)
Today we have many molecules available.
1:27
S… Speaker 2 (EARLY_POD_1-ai)
Today we have two molecules available.
1:30
S… Speaker 2 (EARLY_POD_1-ai)
One is Tuz Hepatite,
1:31
S… Speaker 2 (EARLY_POD_1-ai)
which is known as Muzaro.
1:32
S… Speaker 2 (EARLY_POD_1-ai)
The other is Simogiptrice.
1:34
S… Speaker 2 (EARLY_POD_1-ai)
There are many generics available in the market.
1:37
S… Speaker 2 (EARLY_POD_1-ai)
From zero,
1:38
S… Speaker 2 (EARLY_POD_1-ai)
the data tells us that it is 20 to 25 %
1:42
S… Speaker 2 (EARLY_POD_1-ai)
weight reduction.
1:43
S… Speaker 2 (EARLY_POD_1-ai)
If you reach maximum tolerated dose,
1:45
S… Speaker 2 (EARLY_POD_1-ai)
it is 10 to 15 %
1:49
S… Speaker 2 (EARLY_POD_1-ai)
weight reduction.
1:50
S… Speaker 2 (EARLY_POD_1-ai)
But if you can increase the dose,
1:51
S… Speaker 2 (EARLY_POD_1-ai)
it is 20 % weight reduction.
1:55
S… Speaker 1 (EARLY_POD_1-ai)
And how much weight loss can you
1:59
S… Speaker 1 (EARLY_POD_1-ai)
achieve?
2:03
S… Speaker 2 (EARLY_POD_1-ai)
Usually over M .E .R.
2:07
S… Speaker 2 (EARLY_POD_1-ai)
In clinics,
2:08
S… Speaker 2 (EARLY_POD_1-ai)
we have different weight reductions.
2:10
S… Speaker 2 (EARLY_POD_1-ai)
Some patients have a lot of weight loss.
2:12
S… Speaker 2 (EARLY_POD_1-ai)
Some patients have a lot of weight loss.
2:13
S… Speaker 2 (EARLY_POD_1-ai)
Some patients have a lot of weight loss.
2:14
S… Speaker 2 (EARLY_POD_1-ai)
So your genetics will depend on it,
2:16
S… Speaker 2 (EARLY_POD_1-ai)
but usually it will take a year.
2:17
S… Speaker 2 (EARLY_POD_1-ai)
Got it.
2:18
S… Speaker 1 (EARLY_POD_1-ai)
So, if someone takes weight loss for 6 months,
2:22
S… Speaker 1 (EARLY_POD_1-ai)
9 months,
2:23
S… Speaker 1 (EARLY_POD_1-ai)
1 year, they add up.
2:26
S… Speaker 1 (EARLY_POD_1-ai)
So,
2:27
S… Speaker 1 (EARLY_POD_1-ai)
how do you guide this investment?
2:29
S… Speaker 1 (EARLY_POD_1-ai)
So,
2:32
S… Speaker 2 (EARLY_POD_1-ai)
if you think about long term,
2:37
S… Speaker 2 (EARLY_POD_1-ai)
If we have 50 to 20 % weight reduction,
2:40
S… Speaker 2 (EARLY_POD_1-ai)
then we have a lot of chances of heart problems.
2:43
S… Speaker 2 (EARLY_POD_1-ai)
We have a lot of chances of osteoarthritis.
2:47
S… Speaker 2 (EARLY_POD_1-ai)
We have a lot of chances of osteoarthritis.
2:49
S… Speaker 2 (EARLY_POD_1-ai)
We have a lot of sleep.
2:50
S… Speaker 2 (EARLY_POD_1-ai)
We have a lot of sleep.
2:52
S… Speaker 2 (EARLY_POD_1-ai)
We have a lot of sleep.
2:53
S… Speaker 2 (EARLY_POD_1-ai)
We have a lot of sleep.
2:55
S… Speaker 2 (EARLY_POD_1-ai)
We have a lot of sleep.
2:57
S… Speaker 2 (EARLY_POD_1-ai)
We have a lot of
3:03
S… Speaker 1 (EARLY_POD_1-ai)
sleep.
3:03
S… Speaker 2 (EARLY_POD_1-ai)
These things we were not able to do before.
3:05
S… Speaker 2 (EARLY_POD_1-ai)
So overall cost is very easy.
3:08
S… Speaker 1 (EARLY_POD_1-ai)
All those costs will be very easy
3:12
S… Speaker 1 (EARLY_POD_1-ai)
and uncomfortable.
3:15
S… Speaker 1 (EARLY_POD_1-ai)
So if we talk about cost,
3:19
S… Speaker 1 (EARLY_POD_1-ai)
GLP -1's of many Indian variants,
3:21
S… Speaker 1 (EARLY_POD_1-ai)
we are saying generic question.
3:33
S… Speaker 2 (EARLY_POD_1-ai)
So India is actually called world's pharmacy.
3:36
S… Speaker 2 (EARLY_POD_1-ai)
We are able
3:40
S… Speaker 2 (EARLY_POD_1-ai)
to produce medications at a very low cost.
3:43
S… Speaker 2 (EARLY_POD_1-ai)
And same holds true for simaglutida as well.
3:49
S… Speaker 2 (EARLY_POD_1-ai)
All of these molecules have gone through request rates.
4:02
S… Speaker 2 (EARLY_POD_1-ai)
So I believe RDCJ is doing a good job.
4:04
S… Speaker 1 (EARLY_POD_1-ai)
And this medication is not only in India,
4:06
S… Speaker 1 (EARLY_POD_1-ai)
in fact,
4:07
S… Speaker 2 (EARLY_POD_1-ai)
going abroad. So I again,
4:10
S… Speaker 2 (EARLY_POD_1-ai)
I hold my hope.
4:12
S… Speaker 2 (EARLY_POD_1-ai)
I come to my same statement that India is world's pharmacy and this
4:16
S… Speaker 2 (EARLY_POD_1-ai)
is going to be.
4:17
S… Speaker 2 (EARLY_POD_1-ai)
True for this model.
4:18
S… Speaker 1 (EARLY_POD_1-ai)
Okay. And now,
4:20
S… Speaker 1 (EARLY_POD_1-ai)
these generic generic versions are going to see many brands.
4:23
S… Speaker 1 (EARLY_POD_1-ai)
So,
4:25
S… Speaker 1 (EARLY_POD_1-ai)
in these brands, there will be differences in many cases.
4:28
S… Speaker 1 (EARLY_POD_1-ai)
What do you think mostly similar?
4:29
S… Speaker 2 (EARLY_POD_1-ai)
So,
4:30
S… Speaker 2 (EARLY_POD_1-ai)
we should definitely know about these all molecules.
4:33
S… Speaker 2 (EARLY_POD_1-ai)
When you have to use a molecule,
4:36
S… Speaker 2 (EARLY_POD_1-ai)
how it is produced,
4:38
S… Speaker 2 (EARLY_POD_1-ai)
what is the purification process,
4:40
S… Speaker 2 (EARLY_POD_1-ai)
what is the data behind it.
4:42
S… Speaker 2 (EARLY_POD_1-ai)
If you understand all of these things,
4:44
S… Speaker 2 (EARLY_POD_1-ai)
then use it.
4:45
S… Speaker 2 (EARLY_POD_1-ai)
How do you think it's properly?
4:47
S… Speaker 1 (EARLY_POD_1-ai)
Okay, my next question is that the GLP
4:52
S… Speaker 1 (EARLY_POD_1-ai)
-1 medication is written as an endocrinologist
4:56
S… Speaker 1 (EARLY_POD_1-ai)
or an internal medicine specialist.
5:00
S… Speaker 2 (EARLY_POD_1-ai)
We can see that every type of doctor is prescribed.
5:02
S… Speaker 3 (EARLY_POD_1-ai)
We only see the problems.
5:04
S… Speaker 3 (EARLY_POD_1-ai)
We only see the effects.
5:06
S… Speaker 3 (EARLY_POD_1-ai)
But we also see the problems.
5:09
S… Speaker 3 (EARLY_POD_1-ai)
Like gastric issues.
5:12
S… Speaker 3 (EARLY_POD_1-ai)
Nausea,
5:13
S… Speaker 3 (EARLY_POD_1-ai)
vomiting, diarrhea,
5:14
S… Speaker 3 (EARLY_POD_1-ai)
constipation.
5:15
S… Speaker 3 (EARLY_POD_1-ai)
These problems you can manage medically.
5:18
S… Speaker 3 (EARLY_POD_1-ai)
Especially when you are giving a diabetic patient and
5:22
S… Speaker 3 (EARLY_POD_1-ai)
diarrhea.
5:23
S… Speaker 3 (EARLY_POD_1-ai)
Then you will get a doctor who will
5:27
S… Speaker 3 (EARLY_POD_1-ai)
see all the problems.
5:29
S… Speaker 3 (EARLY_POD_1-ai)
which can only treat your diarrhea.
5:30
S… Speaker 3 (EARLY_POD_1-ai)
Now,
5:32
S… Speaker 3 (EARLY_POD_1-ai)
with that diarrhea, your sugars are low and you need to go down to sugar.
5:36
S… Speaker 3 (EARLY_POD_1-ai)
You can go down to hypoglycemia.
5:37
S… Speaker 3 (EARLY_POD_1-ai)
You can change electrolytes.
5:39
S… Speaker 3 (EARLY_POD_1-ai)
This is why the package is written on internal medicine
5:43
S… Speaker 1 (EARLY_POD_1-ai)
specialist.
5:43
S… Speaker 1 (EARLY_POD_1-ai)
Obviously,
5:45
S… Speaker 2 (EARLY_POD_1-ai)
people are very cost sensitive.
5:49
S… Speaker 2 (EARLY_POD_1-ai)
Price sensitivity is very high.
5:52
S… Speaker 2 (EARLY_POD_1-ai)
There are many cases where people
5:56
S… Speaker 2 (EARLY_POD_1-ai)
buy TRP -1 medications in pharmacies.
5:59
S… Speaker 2 (EARLY_POD_1-ai)
If you want to take a prescription,
6:00
S… Speaker 2 (EARLY_POD_1-ai)
if you want to take these things,
6:03
S… Speaker 2 (EARLY_POD_1-ai)
what is needed?
6:05
S… Speaker 1 (EARLY_POD_1-ai)
So,
6:06
S… Speaker 3 (EARLY_POD_1-ai)
we need to keep a government case with surveillance because there
6:10
S… Speaker 3 (EARLY_POD_1-ai)
are no such damage to which problems are not created.
6:13
S… Speaker 3 (EARLY_POD_1-ai)
If they manage them in the right way,
6:15
S… Speaker 3 (EARLY_POD_1-ai)
if they manage them in the right way,
6:17
S… Speaker 3 (EARLY_POD_1-ai)
if they manage them in the right way, if they give them the right patients.
6:32
S… Speaker 3 (EARLY_POD_1-ai)
So if we talk about
6:38
S… Speaker 1 (EARLY_POD_1-ai)
side effects,
6:39
S… Speaker 2 (EARLY_POD_1-ai)
such as GI side effects,
6:41
S… Speaker 2 (EARLY_POD_1-ai)
people are talking a lot
6:46
S… Speaker 2 (EARLY_POD_1-ai)
about three things.
6:48
S… Speaker 2 (EARLY_POD_1-ai)
GLP -1's pancreatitis,
6:50
S… Speaker 2 (EARLY_POD_1-ai)
GLP -1's blindness and GLP -1's thyroid cancer.
6:54
S… Speaker 1 (EARLY_POD_1-ai)
So,
6:55
S… Speaker 3 (EARLY_POD_1-ai)
when I talk to my patients,
6:58
S… Speaker 3 (EARLY_POD_1-ai)
I will tell them
7:03
S… Speaker 3 (EARLY_POD_1-ai)
that GLP -1's pancreatitis or pancreatic
7:07
S… Speaker 3 (EARLY_POD_1-ai)
cancer or eye problem or blindness.
7:22
S… Speaker 3 (EARLY_POD_1-ai)
So if you look at the actual numbers,
7:25
S… Speaker 3 (EARLY_POD_1-ai)
these are very less numbers.
7:36
S… Speaker 3 (EARLY_POD_1-ai)
Even obesity in Na1 and IFTs in
7:40
S… Speaker 3 (EARLY_POD_1-ai)
Na1 incidence of Na1,
7:41
S… Speaker 3 (EARLY_POD_1-ai)
so is it the immediate reduction of drugs or something else?
7:45
S… Speaker 3 (EARLY_POD_1-ai)
We also try to understand this.
7:46
S… Speaker 3 (EARLY_POD_1-ai)
Similarly for medullary cancer,
7:49
S… Speaker 3 (EARLY_POD_1-ai)
the thyroid cancer is the latest publication of the last week
7:54
S… Speaker 3 (EARLY_POD_1-ai)
that practically it is not a risk associated with
7:58
S… Speaker 1 (EARLY_POD_1-ai)
the GMP1.
7:59
S… Speaker 3 (EARLY_POD_1-ai)
And pancreatitis,
8:01
S… Speaker 3 (EARLY_POD_1-ai)
if someone has pancreatitis,
8:10
S… Speaker 3 (EARLY_POD_1-ai)
Other than that pancreatitis caress is very complex.
8:14
S… Speaker 2 (EARLY_POD_1-ai)
So can you give GLP -1 use pancreatitis?
8:17
S… Speaker 1 (EARLY_POD_1-ai)
Very rare,
8:18
S… Speaker 1 (EARLY_POD_1-ai)
very rare.
8:20
S… Speaker 3 (EARLY_POD_1-ai)
Over past 20 years.
8:22
S… Speaker 3 (EARLY_POD_1-ai)
So I have started using liragrutide way back in 2009 and it is
8:27
S… Speaker 3 (EARLY_POD_1-ai)
2026 now.
8:29
S… Speaker 3 (EARLY_POD_1-ai)
I can't even remember seeing issues.
8:30
S… Speaker 3 (EARLY_POD_1-ai)
If you're using it again,
8:33
S… Speaker 3 (EARLY_POD_1-ai)
like you asked me,
8:34
S… Speaker 3 (EARLY_POD_1-ai)
if you're using it for the correct indication,
8:37
S… Speaker 3 (EARLY_POD_1-ai)
if you're using it in the correct patient,
8:38
S… Speaker 1 (EARLY_POD_1-ai)
you're not taking that.
8:40
S… Speaker 4 (EARLY_POD_1-ai)
Okay.
8:40
S… Speaker 2 (EARLY_POD_1-ai)
So results
8:47
S… Speaker 3 (EARLY_POD_1-ai)
have been really cut.
8:48
S… Speaker 3 (EARLY_POD_1-ai)
Results are actually
8:52
S… Speaker 3 (EARLY_POD_1-ai)
gratifying not only in the patient's weight loss,
8:55
S… Speaker 3 (EARLY_POD_1-ai)
but I can actually see life coming back to them.
8:58
S… Speaker 3 (EARLY_POD_1-ai)
A mother has started playing with the daughter again.
9:02
S… Speaker 3 (EARLY_POD_1-ai)
So that was something that I heard.
9:04
S… Speaker 3 (EARLY_POD_1-ai)
That was a story in my clinic.
9:06
S… Speaker 3 (EARLY_POD_1-ai)
A 142 KT girl.
9:09
S… Speaker 3 (EARLY_POD_1-ai)
Now she is 108.
9:10
S… Speaker 3 (EARLY_POD_1-ai)
And she actually told me,
9:12
S… Speaker 3 (EARLY_POD_1-ai)
sir, my relationships are so good.
9:14
S… Speaker 3 (EARLY_POD_1-ai)
So actually the molecule works really well.
9:18
S… Speaker 3 (EARLY_POD_1-ai)
And what happens with these molecules is that one of my
9:22
S… Speaker 3 (EARLY_POD_1-ai)
patients who took TLC1 from me,
9:25
S… Speaker 3 (EARLY_POD_1-ai)
she went to a marriage and actually I got six more patients after that.
9:29
S… Speaker 1 (EARLY_POD_1-ai)
They asked,
9:31
S… Speaker 1 (EARLY_POD_1-ai)
what have you done?
9:32
S… Speaker 1 (EARLY_POD_1-ai)
What is changing your life?
9:34
S… Speaker 1 (EARLY_POD_1-ai)
It can be life -changing.
9:36
S… Speaker 3 (EARLY_POD_1-ai)
You can actually see the results.
9:39
S… Speaker 1 (EARLY_POD_1-ai)
Wow,
9:40
S… Speaker 2 (EARLY_POD_1-ai)
that's really powerful.
9:41
S… Speaker 2 (EARLY_POD_1-ai)
What is your message to all?
9:45
S… Speaker 2 (EARLY_POD_1-ai)
overweight or obese people who feel any kind of stigma
9:49
S… Speaker 2 (EARLY_POD_1-ai)
or judgment around using GLP -1s?
9:53
S… Speaker 1 (EARLY_POD_1-ai)
See,
9:54
S… Speaker 3 (EARLY_POD_1-ai)
what I'll say is meet a qualified person.
9:58
S… Speaker 3 (EARLY_POD_1-ai)
Meet a qualified person who can actually guide you,
10:01
S… Speaker 3 (EARLY_POD_1-ai)
whether you want,
10:03
S… Speaker 3 (EARLY_POD_1-ai)
whether you'll be requiring or you'll not be requiring,
10:05
S… Speaker 3 (EARLY_POD_1-ai)
that will depend on your clinical status at that time.
10:12
S… Speaker 3 (EARLY_POD_1-ai)
If you have a need for it,
10:15
S… Speaker 3 (EARLY_POD_1-ai)
then you should take it.
10:16
S… Speaker 3 (EARLY_POD_1-ai)
Because in long run,
10:18
S… Speaker 3 (EARLY_POD_1-ai)
obesity problems are bigger than GLP
10:22
S… Speaker 3 (EARLY_POD_1-ai)
-1. Like many people
10:27
S… Speaker 2 (EARLY_POD_1-ai)
who are obese or overweight,
10:29
S… Speaker 2 (EARLY_POD_1-ai)
they say that they naturally try
10:34
S… Speaker 2 (EARLY_POD_1-ai)
to see.
10:37
S… Speaker 2 (EARLY_POD_1-ai)
So, I
10:43
S… Speaker 3 (EARLY_POD_1-ai)
always tend to agree with that.
10:44
S… Speaker 3 (EARLY_POD_1-ai)
I never say,
10:46
S… Speaker 1 (EARLY_POD_1-ai)
don't do this.
10:47
S… Speaker 3 (EARLY_POD_1-ai)
Why I say so is,
10:49
S… Speaker 3 (EARLY_POD_1-ai)
because lifestyle modifications,
10:51
S… Speaker 3 (EARLY_POD_1-ai)
I always want patients to know GLP.
10:53
S… Speaker 3 (EARLY_POD_1-ai)
I definitely tell them,
10:55
S… Speaker 3 (EARLY_POD_1-ai)
yes, I am with you,
10:57
S… Speaker 1 (EARLY_POD_1-ai)
and I am with you,
10:58
S… Speaker 1 (EARLY_POD_1-ai)
and I will tell you.
10:59
S… Speaker 3 (EARLY_POD_1-ai)
We will go
11:03
S… Speaker 3 (EARLY_POD_1-ai)
through this journey together.
11:04
S… Speaker 3 (EARLY_POD_1-ai)
And let's look at the results at 12 weeks.
11:07
S… Speaker 3 (EARLY_POD_1-ai)
If we don't reduce adequate weight,
11:09
S… Speaker 3 (EARLY_POD_1-ai)
then we will again talk about this market.
11:11
S… Speaker 3 (EARLY_POD_1-ai)
So again,
11:12
S… Speaker 3 (EARLY_POD_1-ai)
I will tell my physician friends,
11:15
S… Speaker 3 (EARLY_POD_1-ai)
don't be in a hurry.
11:17
S… Speaker 3 (EARLY_POD_1-ai)
Let the patient take his or her time,
11:20
S… Speaker 3 (EARLY_POD_1-ai)
let them understand and it can be started on a later stage at any point.
11:23
S… Speaker 2 (EARLY_POD_1-ai)
Yeah, very well said,
11:25
S… Speaker 2 (EARLY_POD_1-ai)
very very strong.
11:26
S… Speaker 2 (EARLY_POD_1-ai)
A lot of people who once consider weight
11:30
S… Speaker 2 (EARLY_POD_1-ai)
loss are very scared that your bones will be done,
11:33
S… Speaker 2 (EARLY_POD_1-ai)
you will have a lot of bone loss.
11:35
S… Speaker 2 (EARLY_POD_1-ai)
Have you seen anything like this?
11:37
S… Speaker 3 (EARLY_POD_1-ai)
If you have a proper doctor,
11:40
S… Speaker 3 (EARLY_POD_1-ai)
care and therapy medications,
11:41
S… Speaker 3 (EARLY_POD_1-ai)
there are no such problems.
11:44
S… Speaker 3 (EARLY_POD_1-ai)
problems if you are not exercising and you are losing a lot of muscle along
11:48
S… Speaker 3 (EARLY_POD_1-ai)
with it, then you will also loosen all of your both mental with that.
11:52
S… Speaker 3 (EARLY_POD_1-ai)
If you take proper consultations,
11:55
S… Speaker 3 (EARLY_POD_1-ai)
you will follow proper diet,
11:56
S… Speaker 3 (EARLY_POD_1-ai)
proper calcium,
11:59
S… Speaker 3 (EARLY_POD_1-ai)
vitamin D and proper exercise.
12:02
S… Speaker 3 (EARLY_POD_1-ai)
If you are exercising,
12:03
S… Speaker 3 (EARLY_POD_1-ai)
if you are doing resistance training,
12:05
S… Speaker 1 (EARLY_POD_1-ai)
then these problems actually arise.
12:07
S… Speaker 2 (EARLY_POD_1-ai)
When people have already bone density issues or arthritis,
12:10
S… Speaker 2 (EARLY_POD_1-ai)
there are such things.
12:12
S… Speaker 3 (EARLY_POD_1-ai)
Again,
12:13
S… Speaker 3 (EARLY_POD_1-ai)
I believe osteoarthritis is one of the indications for you.
12:15
S… Speaker 3 (EARLY_POD_1-ai)
Because if your weight is reduced,
12:17
S… Speaker 3 (EARLY_POD_1-ai)
the pressure on your joints is reduced and it is actually helping
12:21
S… Speaker 1 (EARLY_POD_1-ai)
those patients.
12:22
S… Speaker 4 (EARLY_POD_1-ai)
Okay.
12:23
S… Speaker 2 (EARLY_POD_1-ai)
So, you suggest this.
12:24
S… Speaker 3 (EARLY_POD_1-ai)
Osteoarthritis is one of the indications for you.
12:28
S… Speaker 4 (EARLY_POD_1-ai)
Okay.
12:28
S… Speaker 2 (EARLY_POD_1-ai)
GLP -1s,
12:30
S… Speaker 2 (EARLY_POD_1-ai)
what age group do you prescribe for weight?
12:34
S… Speaker 2 (EARLY_POD_1-ai)
Lowest and highest.
12:36
S… Speaker 3 (EARLY_POD_1-ai)
So, current indications it is not indicated before
12:40
S… Speaker 3 (EARLY_POD_1-ai)
AT. So,
12:41
S… Speaker 3 (EARLY_POD_1-ai)
I would describe in before I get it.
12:43
S… Speaker 3 (EARLY_POD_1-ai)
So, tiraglutak is one of the drug that has been approved and we can use if
12:47
S… Speaker 3 (EARLY_POD_1-ai)
the patient is obese and is lesser aiding years of age.
12:53
S… Speaker 3 (EARLY_POD_1-ai)
If I go to the elder age group,
12:55
S… Speaker 3 (EARLY_POD_1-ai)
again it depends on the functional status.
12:57
S… Speaker 3 (EARLY_POD_1-ai)
It is not age that is important.
12:59
S… Speaker 1 (EARLY_POD_1-ai)
Okay.
13:00
S… Speaker 3 (EARLY_POD_1-ai)
If your patient is functionally good,
13:02
S… Speaker 3 (EARLY_POD_1-ai)
like is walking,
13:04
S… Speaker 3 (EARLY_POD_1-ai)
you understand that the patient will
13:08
S… Speaker 3 (EARLY_POD_1-ai)
be able to exercise.
13:09
S… Speaker 3 (EARLY_POD_1-ai)
I'll be very happy to describe ELP1 to that patient.
13:13
S… Speaker 3 (EARLY_POD_1-ai)
But a person who is sedentary and I
13:17
S… Speaker 3 (EARLY_POD_1-ai)
understand that the functional status is not that good.
13:21
S… Speaker 1 (EARLY_POD_1-ai)
probably I'd be a bit skeptical.
13:22
S… Speaker 1 (EARLY_POD_1-ai)
Okay.
13:23
S… Speaker 1 (EARLY_POD_1-ai)
Okay.
13:23
S… Speaker 2 (EARLY_POD_1-ai)
That's super helpful.
13:24
S… Speaker 2 (EARLY_POD_1-ai)
All right.
13:25
S… Speaker 2 (EARLY_POD_1-ai)
Thank you so much,
13:27
S… Speaker 1 (EARLY_POD_1-ai)
Dr. Adur.
13:27
S… Speaker 2 (EARLY_POD_1-ai)
You were phenomenal as always.
13:28
S… Speaker 2 (EARLY_POD_1-ai)
Thanks for sharing your insights on GLP -1s.
13:31
S… Speaker 2 (EARLY_POD_1-ai)
Unko safely kaise consume karna chahiye,
13:32
S… Speaker 2 (EARLY_POD_1-ai)
kis guidance mein ranna chahiye.
13:33
S… Speaker 2 (EARLY_POD_1-ai)
So really appreciate you.
13:35
S… Speaker 3 (EARLY_POD_1-ai)
Thank you.
13:35
S… Speaker 1 (EARLY_POD_1-ai)
Thank you.

Transkrip ini dibuat oleh AI (pengakuan bicara otomatis). Mungkin mengandung kesalahan å verifikasi terhadap audio asli untuk penggunaan kritis. Kebijakan AI

❤️ Suka STT.ai? Beri tahu teman-temanmu!
Ringkasan
Klik Summarize untuk membuat ringkasan AI dari transkrip ini.
Ringkasan...
Tanyakan AI Tentang Transcript Ini
Tanyakan apa saja tentang transkrip ini, AI akan menemukan bagian yang relevan dan jawaban.
Menandakan Yang Lain